Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target ...

Analyst Gena Wang of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Capricor Therapeutics (NASDAQ:CAPR) stock rose 5% in midday trading Friday after the company reported positive long-term data ...

On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Originally published in Quest Diagnostics' 2023 Corporate Responsibility Report We continued to grow access to and ...

Recent Transaction Overview On September 30, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a significant adjustment to ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...

Precision medicine offers tailored treatments for rare diseases, addressing genetic variations and improving therapeutic ...